JSPR vs CCHH Comparison

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

CCH Holdings Ltd, through its subsidiaries, operates a specialty hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot. The Group offers catering services in Malaysia and outside Malaysia, mainly under two brands, namely Chicken Claypot House for its chicken hotpot restaurants and Zi Wei Yuan for its fish head hotpot restaurants. It operates or licenses several restaurant outlets, among which include Chicken Claypot House, Zi Wei Yuan, 888 Family Food Courts, and other outlets under the Bibixian, Banbudian Bistro, and Chao Liu Xian Hotpot brands. A large share of its restaurants are located in Malaysia, with additional franchised outlets in Thailand, Indonesia, and China. Geographically, the Group's revenues are all derived from Malaysia.